文献速递产科母胎医学

疑似早产型子痫前期中的胎盘生长因子:证据综述与实施可行性

Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation.
PubMed 文献 · BJOG · 2020-08-26

该综述总结了胎盘生长因子(PlGF)及其与可溶性fms样酪氨酸激酶1(sFlt-1)作为早产型子痫前期生物标志物的证据,指出基于PlGF的检测可加速诊断并通过风险分层减少孕产妇不良结局。综述还描述了在临床实践中实施PlGF检测的可行性与挑战,目前该检测已在多个国家逐步开展。

要点

  • PlGF与sFlt-1是早产型子痫前期的有价值生物标志物,可加速诊断。
  • 基于PlGF的检测通过风险分层减少孕产妇不良结局,对高风险孕妇加强监测。
  • 基于PlGF的检测已在多个国家逐步进入临床实践。

核心结论

  • 血管生成生物标志物包括PlGF和sFlt-1是早产型子痫前期的有价值生物标志物,可加速诊断并通过风险分层减少孕产妇不良结局。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 基于PlGF的检测可加速诊断并通过风险分层减少孕产妇不良结局,对高风险孕妇加强监测。
  • 基于PlGF的检测已在多个国家逐步进入临床实践。

临床怎么用

  • 综述旨在帮助医疗服务提供者理解基于PlGF检测的证据,并描述实施的可行性与挑战。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite extensive research, the pathophysiology and prevention of pre-eclampsia remain elusive, diagnosis is challenging, and pre-eclampsia remains associated with adverse maternal and perinatal outcomes. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing is increasingly being implemented in clinical practice in several countries. This review provides healthcare providers with an understanding of the evidence for PlGF-based testing and describes the practicalities and challenges to implementation. TWEETABLE ABSTRACT: Placental growth factor in pre-eclampsia: evidence and implementation of testing.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Hurrell A, Beardmore-Gray A, Duhig K, et al. Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation. BJOG. 2020. PMID: 32701207. doi:10.1111/1471-0528.16425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。